Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL102 in Advanced Solid Tumors
NCT04726332Phase 1Terminated
- Sponsor
- Exelixis, Inc.
- Start
- Feb 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tacaciclib in solid tumor, triple negative breast cancer (TNBC), Hormone-Receptor-Positive Breast Cancer and 2 more (6 arms), sponsored by Exelixis, Inc. Primary endpoints: Maximum Tolerated Dose / Recommended Dose at 18 months and Objective Response Rate at 12 months. Started Feb 2021; status: terminated.
02
Drugs
tacaciclib
03
Conditions
solid tumortriple negative breast cancer (TNBC)Hormone-Receptor-Positive Breast Cancerprostate cancer (PCa)epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT04726332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04726332.